Chemical formula: C₂₅H₂₅F₃N₄O₆ Molecular mass: 534.492 g/mol
The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J04AK06 | J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AK Other drugs for treatment of tuberculosis | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| DELTYBA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| DELTYBA Dispersible tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Delamanid is an active ingredient of these brands:
Austria (AT)Croatia (HR)Estonia (EE)France (FR)Hong Kong (HK)Ireland (IE)Japan (JP)Lithuania (LT)Poland (PL)Romania (RO)South Africa (ZA)Spain (ES)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
